
The longitudinal study used the Enroll-HD database to evaluate the impact of β-blockers on Huntington disease (HD) progression in 174 premanifest HD (preHD) and 149 early motor-manifest HD (mmHD) patients, matched with non–β-blocker users. β-blocker use was associated with a reduced annualized hazard of receiving a motor diagnosis in preHD (HR 0.66; 95% CI, 0.46-0.94; p = .02). In mmHD, β-blocker users exhibited slower worsening of motor (MD −0.45; q = 0.025), functional (MD 0.10; q = 0.025), and cognitive (MD 0.33; q = 0.017) scores. These findings suggest β-blockers may have a therapeutic role in HD progression, warranting further studies.
Like
Save
Share